Profiling protein-protein interactions to predict the efficacy of B-cell-lymphoma-2-homology-3 mimetics for acute myeloid leukaemia.
Journal
Nature biomedical engineering
ISSN: 2157-846X
Titre abrégé: Nat Biomed Eng
Pays: England
ID NLM: 101696896
Informations de publication
Date de publication:
18 Jul 2024
18 Jul 2024
Historique:
received:
15
01
2023
accepted:
28
06
2024
medline:
19
7
2024
pubmed:
19
7
2024
entrez:
18
7
2024
Statut:
aheadofprint
Résumé
B-cell-lymphoma-2 (BCL2) homology-3 (BH3) mimetics are inhibitors of protein-protein interactions (PPIs) that saturate anti-apoptotic proteins in the BCL2 family to induce apoptosis in cancer cells. Despite the success of the BH3-mimetic ABT-199 for the treatment of haematological malignancies, only a fraction of patients respond to the drug and most patients eventually develop resistance to it. Here we show that the efficacy of ABT-199 can be predicted by profiling the rewired status of the PPI network of the BCL2 family via single-molecule pull-down and co-immunoprecipitation to quantify more than 20 types of PPI from a total of only 1.2 × 10
Identifiants
pubmed: 39025942
doi: 10.1038/s41551-024-01241-3
pii: 10.1038/s41551-024-01241-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Research Foundation of Korea (NRF)
ID : NRF-2021R1A3B1071354
Organisme : National Research Foundation of Korea (NRF)
ID : NRF-2018M3A9E2023523
Organisme : Korea Health Industry Development Institute (KHIDI)
ID : HI14C1277
Informations de copyright
© 2024. The Author(s).
Références
Alberts, B. The cell as a collection of protein machines: preparing the next generation of molecular biologists. Cell 92, 291–294 (1998).
pubmed: 9476889
doi: 10.1016/S0092-8674(00)80922-8
Li, M. X. et al. BAK alpha6 permits activation by BH3-only proteins and homooligomerization via the canonical hydrophobic groove. Proc. Natl Acad. Sci. USA 114, 7629–7634 (2017).
pubmed: 28673969
pmcid: 5530671
doi: 10.1073/pnas.1702453114
Saxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism, and disease. Cell 168, 960–976 (2017); erratum 169, 361–371 (2017).
pubmed: 28283069
pmcid: 5394987
doi: 10.1016/j.cell.2017.02.004
Broz, P. & Dixit, V. M. Inflammasomes: mechanism of assembly, regulation and signalling. Nat. Rev. Immunol. 16, 407–420 (2016).
pubmed: 27291964
doi: 10.1038/nri.2016.58
Kale, J., Osterlund, E. J. & Andrews, D. W. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 25, 65–80 (2018).
pubmed: 29149100
doi: 10.1038/cdd.2017.186
Kalkavan, H. & Green, D. R. MOMP, cell suicide as a BCL-2 family business. Cell Death Differ. 25, 46–55 (2018).
pubmed: 29053143
doi: 10.1038/cdd.2017.179
Wei, M. C. et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292, 727–730 (2001).
pubmed: 11326099
pmcid: 3049805
doi: 10.1126/science.1059108
Chipuk, J. E., Bouchier-Hayes, L. & Green, D. R. Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario. Cell Death Differ. 13, 1396–1402 (2006).
pubmed: 16710362
doi: 10.1038/sj.cdd.4401963
Moore, V. D. & Letai, A. BH3 profiling – measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett. 332, 202–205 (2013).
doi: 10.1016/j.canlet.2011.12.021
Ku, B., Liang, C. Y., Jung, J. U. & Oh, B. H. Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX. Cell Res. 21, 627–641 (2011).
pubmed: 21060336
doi: 10.1038/cr.2010.149
Willis, S. N. et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-x(L), but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 19, 1294–1305 (2005).
pubmed: 15901672
pmcid: 1142553
doi: 10.1101/gad.1304105
Sarosiek, K. A. et al. BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response. Mol. Cell 51, 751–765 (2013).
pubmed: 24074954
pmcid: 4164233
doi: 10.1016/j.molcel.2013.08.048
Robin, A. Y. et al. Crystal structure of Bax bound to the BH3 peptide of Bim identifies important contacts for interaction. Cell Death Dis. 6, e1809 (2015).
pubmed: 26158515
pmcid: 4650713
doi: 10.1038/cddis.2015.141
Ren, D. et al. BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science 330, 1390–1393 (2010).
pubmed: 21127253
pmcid: 3163443
doi: 10.1126/science.1190217
Czabotar, P. E. et al. Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis. Cell 152, 519–531 (2013).
pubmed: 23374347
doi: 10.1016/j.cell.2012.12.031
Westphal, D., Kluck, R. M. & Dewson, G. Building blocks of the apoptotic pore: how Bax and Bak are activated and oligomerize during apoptosis. Cell Death Differ. 21, 196–205 (2014).
pubmed: 24162660
doi: 10.1038/cdd.2013.139
Zou, Z. L., Tao, T., Li, H. M. & Zhu, X. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci. 10, 31 (2020).
pubmed: 32175074
pmcid: 7063815
doi: 10.1186/s13578-020-00396-1
Laplante, M. & Sabatini, D. M. mTOR signaling in growth control and disease. Cell 149, 274–293 (2012).
pubmed: 22500797
pmcid: 3331679
doi: 10.1016/j.cell.2012.03.017
Shen, H. H. et al. NLRP3: a promising therapeutic target for autoimmune diseases. Autoimmun. Rev. 17, 694–702 (2018).
pubmed: 29729449
doi: 10.1016/j.autrev.2018.01.020
Heneka, M. T., McManus, R. M. & Latz, E. Inflammasome signalling in brain function and neurodegenerative disease. Nat. Rev. Neurosci. 19, 610–621 (2018).
pubmed: 30206330
doi: 10.1038/s41583-018-0055-7
Um, H. D. Bcl-2 family proteins as regulators of cancer cell invasion and metastasis: a review focusing on mitochondrial respiration and reactive oxygen species. Oncotarget 7, 5193–5203 (2016).
pubmed: 26621844
doi: 10.18632/oncotarget.6405
Kelly, P. N. & Strasser, A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ. 18, 1414–1424 (2011).
pubmed: 21415859
pmcid: 3149740
doi: 10.1038/cdd.2011.17
Hockings, C. et al. Mcl-1 and Bcl-x(L) sequestration of Bak confers differential resistance to BH3-only proteins. Cell Death Differ. 25, 721–734 (2018).
pubmed: 29459767
doi: 10.1038/s41418-017-0010-6
Lu, H. Y. et al. Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials. Signal Transduct. Target. Ther. 5, 213 (2020).
pubmed: 32968059
pmcid: 7511340
doi: 10.1038/s41392-020-00315-3
Cory, S., Roberts, A. W., Colman, P. M. & Adams, J. M. Targeting BCL-2-like proteins to kill cancer cells. Trends Cancer 2, 443–460 (2016).
pubmed: 28741496
doi: 10.1016/j.trecan.2016.07.001
Ashkenazi, A., Fairbrother, W. J., Leverson, J. D. & Souers, A. J. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat. Rev. Drug Discov. 16, 273–284 (2017).
pubmed: 28209992
doi: 10.1038/nrd.2016.253
Billard, C. BH3 mimetics: status of the field and new developments. Mol. Cancer Ther. 12, 1691–1700 (2013).
pubmed: 23974697
doi: 10.1158/1535-7163.MCT-13-0058
Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421–3428 (2008).
pubmed: 18451170
doi: 10.1158/0008-5472.CAN-07-5836
Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202–208 (2013).
pubmed: 23291630
doi: 10.1038/nm.3048
Stilgenbauer, S. et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 17, 768–778 (2016).
pubmed: 27178240
doi: 10.1016/S1470-2045(16)30019-5
Wei, A. H. et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J. Clin. Oncol. 37, 1277–1284 (2019).
pubmed: 30892988
pmcid: 6524989
doi: 10.1200/JCO.18.01600
DiNardo, C. D. et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133, 7–17 (2019).
pubmed: 30361262
pmcid: 6318429
doi: 10.1182/blood-2018-08-868752
Townsend, P. A., Kozhevnikova, M. V., Cexus, O. N. F., Zamyatnin, A. A. & Soond, S. M. BH3-mimetics: recent developments in cancer therapy. J. Exp. Clin. Cancer Res. 40, 355 (2021).
pubmed: 34753495
pmcid: 8576916
doi: 10.1186/s13046-021-02157-5
Jameson, J. L. & Longo, D. L. Precision medicine – personalized, problematic, and promising. N. Engl. J. Med. 372, 2229–2234 (2015).
pubmed: 26014593
doi: 10.1056/NEJMsb1503104
Seymour, J. F. et al. Bcl-2 inhibitor ABT-199 (GDC-0199) monotherapy shows anti-tumor activity including complete remissions in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Blood 122, 872 (2013).
Roberts, A. W. et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 374, 311–322 (2016).
pubmed: 26639348
doi: 10.1056/NEJMoa1513257
Konopleva, M. et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 6, 1106–1117 (2016).
pubmed: 27520294
pmcid: 5436271
doi: 10.1158/2159-8290.CD-16-0313
Pollyea, D. A. et al. Venetoclax in combination with hypomethylating agents induces rapid, deep and durable responses in patients with AML ineligible for intensive therapy. Blood 132, 285 (2018).
doi: 10.1182/blood-2018-99-117179
Guieze, R. et al. Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies. Cancer Cell 36, 369–384.e13 (2019).
pubmed: 31543463
pmcid: 6801112
doi: 10.1016/j.ccell.2019.08.005
Thijssen, R. et al. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Haematologica 100, e302–e306 (2015).
pubmed: 25957396
pmcid: 5004430
Ruvolo, P. P., Deng, X. & May, W. S. Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia 15, 515–522 (2001).
pubmed: 11368354
doi: 10.1038/sj.leu.2402090
Yip, K. W. & Reed, J. C. Bcl-2 family proteins and cancer. Oncogene 27, 6398–6406 (2008).
pubmed: 18955968
doi: 10.1038/onc.2008.307
Blombery, P. et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 9, 342–353 (2019).
pubmed: 30514704
doi: 10.1158/2159-8290.CD-18-1119
Blombery, P. et al. Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. Blood 135, 773–777 (2020).
pubmed: 31951646
pmcid: 7146015
doi: 10.1182/blood.2019004205
Tausch, E. et al. Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. Haematologica 104, e434–e437 (2019).
pubmed: 31004028
pmcid: 6717583
doi: 10.3324/haematol.2019.222588
Pan, R. et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 4, 362–375 (2014).
pubmed: 24346116
doi: 10.1158/2159-8290.CD-13-0609
Punnoose, E. A. et al. Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models. Mol. Cancer Ther. 15, 1132–1144 (2016).
pubmed: 26939706
doi: 10.1158/1535-7163.MCT-15-0730
Davids, M. S. et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J. Clin. Oncol. 35, 826–833 (2017).
pubmed: 28095146
pmcid: 5455685
doi: 10.1200/JCO.2016.70.4320
Song, T. et al. Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding. Br. J. Pharmacol. 173, 471–483 (2016).
pubmed: 26493374
pmcid: 4728412
doi: 10.1111/bph.13370
Villalobos-Ortiz, M., Ryan, J., Mashaka, T. N., Opferman, J. T. & Letai, A. BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics. Cell Death Differ. 27, 999–1007 (2020).
pubmed: 31332296
doi: 10.1038/s41418-019-0391-9
Ryan, J., Montero, J., Rocco, J. & Letai, A. iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry. Biol. Chem. 397, 671–678 (2016).
pubmed: 26910743
doi: 10.1515/hsz-2016-0107
Bhatt, S. et al. Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia. Cancer Cell 38, 872–890.e6 (2020).
pubmed: 33217342
pmcid: 7988687
doi: 10.1016/j.ccell.2020.10.010
Ha, T. et al. Single-molecule fluorescence spectroscopy of enzyme conformational dynamics and cleavage mechanism. Proc. Natl Acad. Sci. USA 96, 893–898 (1999).
pubmed: 9927664
pmcid: 15321
doi: 10.1073/pnas.96.3.893
Jain, A. et al. Probing cellular protein complexes using single-molecule pull-down. Nature 473, 484–488 (2011).
pubmed: 21614075
pmcid: 3103084
doi: 10.1038/nature10016
Lee, H. W. et al. Real-time single-molecule coimmunoprecipitation of weak protein–protein interactions. Nat. Protoc. 8, 2045–2060 (2013).
pubmed: 24071910
doi: 10.1038/nprot.2013.116
Lee, H. W. et al. Real-time single-molecule co-immunoprecipitation analyses reveal cancer-specific Ras signalling dynamics. Nat. Commun. 4, 1505 (2013).
pubmed: 23422673
doi: 10.1038/ncomms2507
Lee, H. W. et al. Profiling of protein-–protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors. Nat. Biomed. Eng. 2, 239–253 (2018).
pubmed: 30936439
doi: 10.1038/s41551-018-0212-3
Choi, B. et al. Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers. Elife 9, e53934 (2020).
pubmed: 32267234
pmcid: 7176432
doi: 10.7554/eLife.53934
Dengler, M. A. et al. BAX activation: mutations near its proposed non-canonical BH3 binding site reveal allosteric changes controlling mitochondrial association. Cell Rep. 27, 359–373.e6 (2019).
pubmed: 30970242
doi: 10.1016/j.celrep.2019.03.040
Peyerl, F. W. et al. Elucidation of some Bax conformational changes through crystallization of an antibody-peptide complex. Cell Death Differ. 14, 447–452 (2007).
pubmed: 16946732
doi: 10.1038/sj.cdd.4402025
Zhang, Z. et al. Bax forms an oligomer via separate, yet interdependent, surfaces. J. Biol. Chem. 285, 17614–17627 (2010).
pubmed: 20382739
pmcid: 2878526
doi: 10.1074/jbc.M110.113456
Antonsson, A. & Persson, J. L. Induction of apoptosis by staurosporine involves the inhibition of expression of the major cell cycle proteins at the G(2)/m checkpoint accompanied by alterations in Erk and Akt kinase activities. Anticancer Res. 29, 2893–2898 (2009).
pubmed: 19661292
Pagliari, L. J. et al. The multidomain proapoptotic molecules Bax and Bak are directly activated by heat. Proc. Natl Acad. Sci. USA 102, 17975–17980 (2005).
pubmed: 16330765
pmcid: 1312392
doi: 10.1073/pnas.0506712102
Dewson, G. et al. Bak activation for apoptosis involves oligomerization of dimers via their alpha6 helices. Mol. Cell 36, 696–703 (2009).
pubmed: 19941828
doi: 10.1016/j.molcel.2009.11.008
Yoo, J., Lee, T. S., Choi, B., Shon, M. J. & Yoon, T. Y. Observing extremely weak protein–protein interactions with conventional single-molecule fluorescence microscopy. J. Am. Chem. Soc. 138, 14238–14241 (2016).
pubmed: 27758101
doi: 10.1021/jacs.6b09542
Srivastava, A. K. et al. BAX-BAK heterodimer as a pharmacodynamic biomarker of on-target drug action of Mcl-1 inhibitors to evaluate in-vivo effectiveness. J. Clin. Oncol. https://doi.org/10.1200/JCO.2018.36.15_suppl.2582 (2018).
doi: 10.1200/JCO.2018.36.15_suppl.2582
pubmed: 30091946
pmcid: 6145833
Zhou, L. Y. & Chang, D. C. Dynamics and structure of the Bax-Bak complex responsible for releasing mitochondrial proteins during apoptosis. J. Cell Sci. 121, 2186–2196 (2008).
pubmed: 18544634
doi: 10.1242/jcs.024703
Willis, S. N. et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315, 856–859 (2007).
pubmed: 17289999
doi: 10.1126/science.1133289
Anderson, M. A. et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood 127, 3215–3224 (2016).
pubmed: 27069256
pmcid: 4920022
doi: 10.1182/blood-2016-01-688796
Chen, H. C. et al. An interconnected hierarchical model of cell death regulation by the BCL-2 family. Nat. Cell Biol. 17, 1270–1281 (2015).
pubmed: 26344567
pmcid: 4589531
doi: 10.1038/ncb3236
Tron, A. E. et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat. Commun. 9, 5341 (2018).
pubmed: 30559424
pmcid: 6297231
doi: 10.1038/s41467-018-07551-w
Matulis, S. M. et al. Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma. Leukemia 33, 1291–1296 (2019).
pubmed: 30679802
pmcid: 6891824
doi: 10.1038/s41375-018-0374-8
Gupta, V. A. et al. Venetoclax ex vivo functional profiling predicts improved progression-free survival. Blood Cancer J. 12, 115 (2022).
pubmed: 35927247
pmcid: 9352682
doi: 10.1038/s41408-022-00710-9
Fraser, C., Ryan, J. & Sarosiek, K. BH3 profiling: a functional assay to measure apoptotic priming and dependencies. Methods Mol. Biol. 1877, 61–76 (2019).
pubmed: 30535998
pmcid: 7325165
doi: 10.1007/978-1-4939-8861-7_4
Del Gaizo Moore, V. & Letai, A. BH3 profiling – measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett. 332, 202–205 (2013).
pubmed: 22230093
doi: 10.1016/j.canlet.2011.12.021
Seyfried, F. et al. Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling. Cell Death Dis. 10, 571 (2019).
pubmed: 31358732
pmcid: 6662703
doi: 10.1038/s41419-019-1801-0
Dohner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129, 424–447 (2017).
pubmed: 27895058
pmcid: 5291965
doi: 10.1182/blood-2016-08-733196
Park, S., Cho, B. S. & Kim, H. J. New agents in acute myeloid leukemia (AML). Blood Res. 55, 14–18 (2020).
doi: 10.5045/br.2020.S003
Roberts, A. W. et al. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood 134, 111–122 (2019).
pubmed: 31023700
pmcid: 6624969
doi: 10.1182/blood.2018882555
Mato, A. R. et al. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica 103, 1511–1517 (2018).
pubmed: 29880613
pmcid: 6119152
doi: 10.3324/haematol.2018.193615
Liu, Z. et al. Direct activation of Bax protein for cancer therapy. Med. Res. Rev. 36, 313–341 (2016).
pubmed: 26395559
doi: 10.1002/med.21379
Walensky, L. D. Targeting BAX to drug death directly. Nat. Chem. Biol. 15, 657–665 (2019).
pubmed: 31209350
doi: 10.1038/s41589-019-0306-6
Liu, Q. et al. Bim escapes displacement by BH3-mimetic anti-cancer drugs by double-bolt locking both Bcl-XL and Bcl-2. Elife 8, e37689 (2019).
pubmed: 30860026
pmcid: 6414199
doi: 10.7554/eLife.37689
Bogner, C. et al. Allosteric regulation of BH3 proteins in Bcl-x(L) complexes enables switch-like activation of Bax. Mol. Cell 77, 901–912.e9 (2020).
pubmed: 32001105
doi: 10.1016/j.molcel.2019.12.025
Alfaro, J. A. et al. The emerging landscape of single-molecule protein sequencing technologies. Nat. Methods 18, 604–617 (2021).
pubmed: 34099939
pmcid: 8223677
doi: 10.1038/s41592-021-01143-1
Chun, C. et al. Nat-Biomed-Eng-2023-Custom-Code. GitHub https://github.com/tyyoonlab-snu/Nat-Biomed-Eng-2023- (2024).
Smith, M. L. & Tahir, S. K. Quantification of BCL-2 family members by flow cytometry. Methods Mol. Biol. 1877, 163–172 (2019).
pubmed: 30536005
doi: 10.1007/978-1-4939-8861-7_11